Kornimate/medical-research-clean huggingface dataset:
endocan, vegf and tnf-alpha levels in periodontal disease and after treatment

Conditions: Periodontal Disease

Summary: the primer aim of the study was to determine serum and gingival crevicular fluid (gcf) endocan levels in periodontal diseases pathogenesis supported with vascular endothelial growth factor (vegf) and tumor necrosis factor alpha (tnf-α) levels.

the study consist of three groups: periodontally healthy individuals (group 1; n = 20), individuals with generalized chronic periodontitis (group 2; n = 20), the same patients with chronic periodontitis after they had been treated with scaling and root planing (srp) were considered as group 3. clinical measurements were recorded; gcf and serum samples were obtained from each participant before and 6 weeks after therapy. endocan, vegf-a and tnf-α levels were measured by enzyme-linked immunosorbent assay.

Eligibility criteria:
group 1 inclusion criteria: * no bone and attachment loss, * gi=0, ppd≤3mm, cal≤3mm * systematically healthy patients group 2 inclusion criteria: * gi\>1, ppd≥5mm, cal≥5mm with alveolar bone loss radiographically. * systematically healthy patients exclusion criteria: * aggressive periodontitis, * oral pathologies, * patients with any other systemic diseases, * pregnant women and those in the lactation period, * patients with smoking habit and taking medication * patients received periodontal therapy in last 6 months

Keywords: endocan protein vegf a tnf-alpha after treatment
fundamental modification of the gut microbiota in the treatment of refractory crohn's disease

Conditions: Crohn's Disease

Summary: to determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active crohn's disease (cd) that is refractory to conventional, immunosuppressive therapy.


Eligibility criteria:
inclusion criteria: * participant is capable of giving informed consent * males or females 18-75 years of age * normal kidney function (defined by normal serum creatinine \[male: \<1.27 mg/dl; female: \<1.03 mg/dl\]) * normal aspartate aminotransferase \[ast\] (\<41 u/l), alanine aminotransferase \[alt\] (\<63 u/l), and alkaline phosphatase (\<126 u/l) * active cd defined as hbi ≥ 7 * crp \> 5 mg/dl or hs-crp \> 10mg/l (or 1mg/dl) or fecal calprotectin (fcp) \> - - 350 mcg/g (within one month of enrollment) * have been treated with one of the following therapies\*\* for at least 8 weeks with primary nonresponse or an initial response, followed by loss of response \[lor\] (self-reported worsening of symptoms for ≥ 7 days): azathioprine, 6-mercaptopurine, methotrexate, adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab, or ustekinumab \*\*these medications must have been administered at standard, therapeutic dosages. exclusion criteria: * known or suspected stricturing disease producing obstructive symptoms * active clostridium difficile infection * unwillingness to provide informed consent * allergy or intolerance to the medications used in this study * history of kidney disease * history of liver disease * pregnant or lactating females * baseline qtc interval on ekg \> 430 in males or \> 450 in females * participants who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
ovarian hyperstimulation syndrome and cabergoline

Conditions: Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome

Summary: cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -i (igf-i), antimullerian hormone (amh), inhibin b and hepatocyte growth factor (hgf) levels in women with pcos and high risk of ovarian hyperstimulation syndrome (ohss).

dopamine agonists have been proposed as a prophylactic treatment for ohss in women with high risk of ohss, however the possible mechanism of action has not been clearly known. in experimental studies, inhibition of vascular endothelial growth factor based pathway was proposed as a possible action of mechanism of dopamine agonists. however the role hepatocyte growth factor (hgf), insulin like growth factor-i (igf-i), inhibin b and antimullerian hormone (amh) on cabergoline action in ohss prevention has not been known.

Eligibility criteria:
inclusion criteria: * development of more than 14 leading follicles larger than 10 mm and serum estradiol more than 3000 pg/ml at the end of ovulation induction with long luteal ovulation induction protocol. * having the criteria of pcos exclusion criteria: * not having the inclusion criteria.
probiotic supplementation as prophylactic for group b β-hemolytic streptococcus (gbs) infection

Conditions: Genitourinary; Infection, Complicating Pregnancy

Summary: streptococcus agalactiae, a group b β-hemolytic streptococcus (gbs), is the leading cause of severe neonatal infection in developed countries. there is growing scientific interest in probiotic supplementation in pregnancy as possible prophylaxis for gbs infections and urine culture positivity.

there is strong scientific evidence that supports the correlation between bacterial vaginosis (bv), a term used to define a change in the vaginal ecosystem, and spontaneous preterm birth. antibiotic treatments are recommended to counteract both the presence of s. agalactiae and the onset of bv. the latter, however, are not without risks, as they can in turn cause alterations in the vaginal microbiota and is associated with an increased risk of miscarriage. recent research have shown that probiotic treatment can help reduc the risk of preterm birth and positivity of group b β-hemolytic streptococcus (gbs) infection. the present study aimed to assess the efficacy and safety of a probiotic inatal® (probiotic mixture containing 10 ml cfu of enterococcus faecium l3, 3 billion cfu of bifidobacterium animalis subsp. lactis bb-12, 3 billion cfu of lactococcus lactis sp38, 3 billion cfu of lacticaseibacillus casei r0215) in pregnant wemen in 24 to 36 weeks of gestation as prophylaxis of gbs infections and urine culture positivity. this was a retrospective, observational, controlled and single centre study.

Eligibility criteria:
inclusion criteria: * pregnant women in 24-36 weeks of gestation period * history of recurrent genitourinary and/or intestinal problems exclusion criteria: * presence of neurological condition * history of cardiovascular disease * history of pulmonary disease * history of renal disease * cancer
examining the relationship between hormone therapy (ht) and cognitive function (the whims-echo study)

Conditions: Dementia

Summary: this is a prospective, observational study of the cohort of older post-menopausal participants in the whi memory study, a sub-cohort of participants in the whi hormone trials. annual cognitive assessments and ascertainment of cognitive impairment enable the continued monitoring of long-term effects of randomization to ht on cognition and identification of predictors of cognitive vulnerability and resilience in older women.

identification of the predictors of cognitive impairment and cognitive resilience among aging women is important because the incidence of mild cognitive impairment (mci) and dementia increases with age and women live the longest. the women's health initiative memory study examined the impact of randomization to hormone therapy (conjugated equine estrogen alone or in combination with medroxyprogesterone vs. placebo) in a subset of participants aged 65-79 years at enrollment into whi and the whi hormone trials. whims revealed an increased risk of all-cause dementia and mci plus poorer global cognitive function among women randomized to ht compared to those receiving placebo. whims echo is a prospective, observational study of the remaining cohort of whims participants following cessation of treatment. annual cognitive assessments of learning, attention, memory, working memory, executive function and language are conducted by telephone by trained staff and adjudication of incident cognitive impairment (mci and dementia) continues. this enables the continued monitoring of long-term effects of randomization to ht on cognition and identification of predictors of cognitive aging and resilience in older women.

Eligibility criteria:
inclusion criteria: * participated in the whims study exclusion criteria * non-english speaking * hearing impaired

Keywords: cognition memory hormone therapy ht
clinical performance of the afgen1 device over a 7-day period

Conditions: Atrial Fibrillation; Afib; Irregular Heart Beat; Arrhythmias, Cardiac; Arrhythmia Atrial; Arrhythmias Paroxysmal; Paroxysmal Atrial Fibrillation

Summary: afgen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ecg is needed to identify episodes of afib. the purpose of this study is to establish the clinical performance of the afib-chek device (a.k.a. device) on human participants.

the primary purpose of this study is to demonstrate that the ecd signal acquired by the afgen1 device is as of adequate quality and is suitable to support its intended use for the detection of afib.

Eligibility criteria:
inclusion criteria: 1. 18+ willing to sign the consent form exclusion criteria: 1. implanted pacemakers 2. implanted cardioverter defibrillators 3. implanted cardiac resynchronization devices 4. potential life-threatening arrythmias 5. physical or mental health conditions that would prevent the person from being able to follow instruc-tions regarding participation in the study 6. open wounds, abraded or irritated skin at the application site 7. planned to undergo a mri during the course of the study duration
a study to test if tev-50717 is effective in relieving tics associated with tourette syndrome (ts)

Conditions: Tourette Syndrome

Summary: standard placebo-controlled, double-blind study design (tev-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with ts.


Eligibility criteria:
inclusion criteria: * participant weighs at least 44 pounds (20 kg) at baseline. * participant meets the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5™) diagnostic criteria for ts and, in the opinion of the investigator, participant, and parent/legal guardian, the participant's active tics are causing distress or impairment. * participant has a tts of 20 or higher on the ygtss at screening and baseline. * participant is able to swallow study medication whole. * -additional criteria apply, please contact the investigator for more information exclusion criteria: * participant has a neurologic disorder other than ts that could obscure the evaluation of tics. * the participant 's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder. * participant has clinically significant depression at screening or baseline. * participant has a history of suicidal intent or related behaviors within 2 years of screening * participant has a history of a previous actual, interrupted, or aborted suicide attempt. * participant has a first-degree relative who has completed suicide. * participant has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder. * participant has received comprehensive behavioral intervention for tics for ts or cognitive behavioral therapy for obsessive-compulsive disorder (ocd) within 4 weeks of screening. * participant has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation within 4 weeks of the screening visit for reduction of tics. * participant has a history of torsades de pointes, congenital long qt syndrome, bradyarrhythmias, or uncompensated heart failure. * participant has participated in an investigational drug or device study and received investigational medicinal product (imp)/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer. * participant is a pregnant or lactating female, or plans to be pregnant during the study. * -additional criteria apply, please contact the investigator for more information
study to evaluate a contact lens lubricating and rewetting drop

Conditions: Dry Eye

Summary: the objective of this study is to evaluate the product performance of investigational lubricating and rewetting drops.


Eligibility criteria:
inclusion criteria: * have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. * adapted wearers of soft contact lenses, wear a lens in each eye, and each lens must be of the same manufacture and brand. * use a lens care system on a regular basis. * wear their habitual lenses (or be willing to wear lenses) a minimum of 8 hours per day. * willing to use drops 4 times per day. exclusion criteria: * participating in a conflicting study. * an active ocular disease, any corneal infiltrative response, or are using any ocular medications. * any scar or neovascularization within the central 4mm of the cornea. * any grade 2 or greater finding during the slit lamp examination * using any systemic or topical medications that will affect ocular physiology or lens performance. * aphakic. * amblyopic. * allergic to any component in the study care products. * have had any corneal surgery.

Keywords: rewetting lubricating eye drops
effect of adding sufentanil to epidural ropivacaine on perioperative metabolic and stress responses in combined general/epidural anaesthesia for geriatric radical retropubic prostatectomy

Conditions: Prostatic Cancer

Summary: the purpose of this study is to compare metabolic and stress responses in combined general/epidural anesthesia in geriatric cancer patients.


Eligibility criteria:
inclusion criteria: * elective rrp for prostatic cancer scheduled in the morning (9-11 a.m.) * patients aged more than 65 years * asa physical status i or ii * absence of contraindications to epidural approach * absence of a history of chronic pain or opioid medication exclusion criteria: * contraindication to epidural catheterization

Keywords: patients of prostatic cancer aged more than 65 years
epidermal growth factor receptor mutations in the blood of patients with advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is looking at epidermal growth factor receptor mutations in the blood of patients with advanced non-small cell lung cancer.

objectives: * determine if epidermal growth factor receptor (egfr) mutation exists in the peripheral blood of patients with advanced non-small cell lung cancer (nsclc). * estimate the frequency of egfr mutation in these patients. * correlate the presence of egfr mutation in blood with egfr mutation in primary or metastatic nsclc tumor block. outline: patients undergo blood collection for analysis of epidermal growth factor receptor mutation by dna sequencing. projected accrual: a total of 50 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed advanced non-small cell lung cancer * must have available tumor tissue block patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
strategy + rehacom for memory rehabilitation in traumatic brain injury (tbi)

Conditions: Traumatic Brain Injury With Loss of Consciousness

Summary: the purpose of this research study is to evaluate the effectiveness of "rehacom," a computerized treatment for memory deficits, in a 16-session, interactive course. following a manualized approach, the rehacom modules will be used for the repeated application of the content acquired during 1-on-1 memory strategy training. the goal is to improve face/name, list and verbal memory of patients who survived a moderate to severe traumatic brain injury.

this randomized clinical trial (rct) consists of 20 chronic moderate-to-severe tbi patients who will receive memory strategy training and complete three memory modules of the rehacom at one of the kessler foundation locations. changes in attention, processing speed, verbal/non-verbal new learning and memory (nlm) and executive control will be assessed via pre/post and 3-month follow-up assessments before and after the 8-10 week intervention. self-report questionnaires will also track functional and emotional outcomes such as mood and anxiety, cognition, quality of life, self-efficacy, deficit awareness, community participation, and readiness for occupational functioning

Eligibility criteria:
inclusion criteria: * able to read and speak english fluently at the 5th grade level (for testing; software has multilingual support) * had a tbi at least 1 year ago * no history of learning disorders during school years * able to use a personal computer (pc) non-stop for 1 hour without health or visual complaints; able to press keyboard buttons.no history of learning disorders exclusion criteria: * actively participating in another intervention study * distance to kessler foundation east hanover or west orange location is more than 20 miles.

Keywords: tbi face memory verbal memory learning cognition memory training pilot study compensatory memory strategies cognitive rehabilitation
effects of combination therapy with alpha-1 blocker (bunazosin or doxazosin) in the treatment of patients with mild to moderate essential hypertension

Conditions: High Blood Pressure

Summary: the purpose of this study is to investigate the efficacy and safety of bunazosin with valsartin compared to doxazosin with valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.

this clinical study will comprise a 1 to 2-week washout period, a 5-week mono therapy period with angiotensinⅱantagonist, and an 8-week alpha blocker add-on treatment period. total study period will be 15 weeks.

Eligibility criteria:
inclusion criteria: subjects with mild to moderate essential hypertension, with the following criteria: 1. washout period (week -2) * male or female subjects aged 20 to 80 years * systolic blood pressure (sbp):140 mm hg but \<180 mm hg and/or diastolic blood pressure (dbp):90 mm hg but \<110 mm hg * subjects who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol 2. angiotensin ii antagonist mono-therapy period (week 0) * subjects with systolic blood pressure \>= 140 mm hg but \ = 90 mm hg but \<110 mm hg * presence of any 2 of the following 4 risk factors * waist circumference: male \> 90 cm, female \> 80 cm * triglycerides \>= 150 mg/dl * hdl cholesterol: male \< 40 mg/dl, female \< 50 mg/dl * fasting glucose \>= 110 mg/dl 3. angiotensin ii antagonist with add-on bunazosin or doxazosin treatment period (week 5) * sbp \>=140 mm hg or decrease \< 10 % or * dbp \>=90 mm hg or decrease \< 10 % comparing the blood pressure at the entry of the angiotensin ii antagonist mono-therapy period. exclusion criteria: subjects with the following conditions are not eligible for participation： a) washout period (week -1 or -2) * subjects with severe hypertension (sbp\>=180 mm hg or dbp\>=110 mm hg). * subjects who have proven or suspected hypersensitivity to quinazoline derivatives * subjects who have a history of alcohol or drug abuse. * subjects with past or present evidence of cancer * subjects who have a past history of arterial fibrillation, heart failure (lvef\<40%), acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia. * subjects who are severely obese (bmi\>30 kg/m2) * women who are pregnant or lactating or suspected of being pregnant. * subjects who have previously participated in any clinical trial of new or unapproved substances within the 12 weeks before starting of washout period * subjects on other anti-hypertensive or lipid-lowering medication * inability to return for scheduled visits or comply with any other aspect of the protocol * subjects with poorly controlled diabetes mellitus (hba1c \> 10%) * subjects with concurrent serious hepatic or renal disorders (defined as ast and/or alt \> 3 times upper normal limit or cr \> 2mg/dl). * subjects who, in the opinion of the investigators, are poor medical candidates or pose any other risk for therapy with an investigational drug.

Keywords: blood pressure sbp dbp
evaluation of the cosmetic outcomes of totally endoscopic cardiac surgery

Conditions: Minimally Invasive Cardiac Surgery; Scar

Summary: totally endoscopic cardiac surgery (tecs) is considered to have aesthetic advantages over conventional median sternotomy due to the smaller incisions. most research regarding tecs focuses on clinical outcomes instead of cosmetic consequences. following surgery, postoperative scarring is unavoidable and may negatively affect the patient's physical and emotional well-being. therefore, this study aims to investigate the cosmesis after tecs.

totally endoscopic cardiac surgery (tecs) is considered to have aesthetic advantages over conventional median sternotomy due to the smaller incisions. most research regarding tecs focuses on clinical outcomes instead of cosmetic consequences. following surgery, postoperative scarring is unavoidable and may negatively affect the patient's physical and emotional well-being. one previous study compared median sternotomy cardiac surgery and tecs in terms of the long-term cosmetic appearance of postoperative scars. they concluded that scars were considered more satisfactory, less painful, and itchy in the tecs group in the chinese population. to our knowledge, this is the only study published regarding cosmetic consequences after tecs. therefore, this study aims to investigate the cosmesis after tecs.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old * patients who can give their informed consent * patients who speak dutch or french exclusion criteria: * patients that previously underwent cardiac surgery * patients that will undergo a combination of cardiac surgeries
effects of renal replacement therapy with hemoadsoption in patients with sepsis

Conditions: Sepsis

Summary: hemoadsorption has been demonstrated to improve clinical and paraclinical results in critically ill patients with sepsis and septic shock. the present study investigates the effects of three consecutive sessions of hemoadsorption, performed in accordance to the local protocol for treating patients with sepsis, on organ failure, severity scores and 30-days mortality. paraclinical results and severity scores were obtained before and after the three consecutive sessions.


Eligibility criteria:
inclusion criteria: * patients with sepsis or septic shock who require hemoadsorption in accordance with local guidelines exclusion criteria: * unsigned informed consent * duration of therapy under 12 hours * death before the three consecutive sessions

Keywords: organ failure renal replacement therapy hemoadsorption